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Bronx and New York, New York
O B J E C T I V E S The purpose of this study was to compare the diagnostic accuracy of cardiac
magnetic resonance (CMR) assessing myocardial viability in patients with chronic left ventricular (LV)
dysfunction due to coronary artery disease using 3 techniques: 1) end-diastolic wall thickness (EDWT);
2) low-dose dobutamine (LDD); and 3) contrast delayed enhancement (DE).
B A C KG ROUND CMR has been proposed to assess myocardial viability over the past decade.
However, the best CMR strategy to evaluate patients being contemplated for revascularization has not
yet been determined. Some centers advocate DE CMR due to its high sensitivity to identify scar, whereas
others favor the use of LDD CMR for its ability to identify contractile reserve.
METHOD S A systematic review of MEDLINE, Cochrane, and Embase for all the prospective trials
assessing myocardial viability in subjects with chronic LV dysfunction using CMR was performed using
a standard approach for meta-analysis for diagnostic tests and a bivariate analysis of sensitivity,
speciﬁcity, positive predictive value (PPV), and negative predictive value (NPV).
R E S U L T S A total of 24 studies of CMR evaluating myocardial viability with 698 patients fulﬁlled the
inclusion criteria. Eleven studies used DE, 9 studies used LDD, and 4 studies used EDWT. Our
meta-analysis indicates that among CMR methods, DE CMR provides the highest sensitivity as well as the
highest NPV (95% and 90%, respectively) for predicting improved segmental LV contractile function after
revascularization, followed by EDWT CMR, whereas LDD CMR demonstrated the lowest sensitivity/NPV
among all modalities. On the other hand, LDD CMR offered the highest speciﬁcity and PPV (91% and
93%, respectively), followed by DE CMR, whereas EDWT showed the lowest of these parameters.
CONC L U S I O N S DE CMR provides the highest sensitivity and NPV, whereas LDD CMR provides the
best speciﬁcity and PPV. In light of these ﬁndings, integrating these 2 methods should provide increased
accuracy in evaluating patients with chronic LV dysfunction being considered for revascularization. (J Am
Coll Cardiol Img 2012;5:494–508) © 2012 by the American College of Cardiology Foundation
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Columbia University College of Physicians & Surgeons, New York, New York. Dr. Garcia is a consultant to TheHeart.org. All
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gadolinium contrast agents for myocardial imaging is not an FDA approved indication.Manuscript received February 22, 2012; accepted February 23, 2012.
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495hortly after the phrase hibernating myocar-
dium was introduced in 1986 and the pos-
sibility for detection of salvageable myocar-
dium in coronary artery disease (CAD) was
identified (1), several different methods of assessing
myocardial viability have been implemented and
tested. Viability tests have become a crucial tool in
evaluating whether patients with congestive heart
failure related to CAD might benefit from revascu-
larization therapy. Revascularization is accomplished
See page 509
in the form of either coronary artery bypass graft
(CABG) or percutaneous coronary intervention
(PCI) (2), both of which have been proven to be
superior to medical therapy in optimizing cardiac
contractility (3).
The most studied noninvasive techniques for
evaluating myocardial viability are dobutamine
stress echocardiography (DSE), positron emission
tomography with fluorine-18 deoxyglucose (PET-
FDG), single-photon emission computed tomogra-
phy (SPECT) with thallium-201 stress–redistribution–
reinjection, thallium-201 late redistribution, and
technetium-99m sestamibi (4). These modalities
rely on the demonstration of wall motion abnor-
malities, preserved myocardial metabolism, cell
membrane integrity, and intact mitochondrial func-
tion in assessing the patient’s myocardial viability,
respectively (5–7). Bax et al. (8) published 2 meta-
analyses evaluating the accuracy of the aforemen-
tioned techniques; the first study in 1997 concluded
that DSE had overall the highest predictive accu-
racy in assessing myocardial viability. His second
study in 2001 concluded that nuclear imaging
rendered higher sensitivities and negative predictive
values (NPV), whereas dobutamine echocardiogra-
phy provided higher specificities and positive pre-
dictive values (PPV) (9).
Over the past decade, newer techniques such as
magnetic resonance imaging (MRI), electroanatomic
mapping, and myocardial contrast echocardiography
have been proposed to assess myocardial viability
(10–12). Cardiac magnetic resonance (CMR) has
gained popularity due to technological innovations
such as electrocardiographic gating and respiratory
motion suppression methods, which facilitate high-
quality cross-sectional images of the heart with supe-
rior spatial resolution (13). Unlike other imaging
modalities, CMR has the advantage of detecting
the percentage of transmural involvement in the pventricular wall, differentiating transmural from
subendocardial infarcts (10).
Previous investigations have fundamentally eval-
uated 3 CMR methods: 1) resting assessment of left
ventricular (LV) end-diastolic wall thickness
(EDWT); 2) low-dose (LDD) dobutamine stress
assessment of contractile reserve; and 3) delayed
contrast enhancement (DE) to assess for scar tissue
(14–16). To date, there have been 3 reviews regard-
ing CMR and myocardial viability in which pooled
data from previous original investigators
were displayed (17–19). More recently,
Schinkel et al. (20) updated the work done
by Bax et al. (8,9) and also included CMR
as a new technique in their analyses. Nev-
ertheless, these included only a limited
number of studies in each CMR modality,
and significant differences among studies
were not accounted for. In the following
meta-analysis, we scrutinize the accuracy
of different techniques using CMR in the
evaluation of myocardial viability in the
extensive literature on this modality.
M E T H O D S
Search strategy. The objective of the cur-
ent analysis was to evaluate the available
rospective trials in which CMR, using at
east 1 of the 3 aforementioned methods,
ssessed LV regional and global function
fter revascularization.
We searched PubMed, Embase, and
he Cochrane Central Register of Clinical
rials (Cochrane Library, Issue 1, 2011)
sing the terms (MRI OR magnetic reso-
ance imaging OR magnetic resonance OR
agnetic resonance spectroscopy OR cardiac
agnetic resonance OR cardiovascular mag-
etic resonance OR contrast-enhanced MRI)
ND (viability OR myocardial viability
R cardiac viability OR viability assess-
ent OR viability test OR viable myocar-
ium OR ventricular dysfunction OR myocardial dys-
unction OR cardiac dysfunction OR ejection fraction
R dysfunctional myocardium OR functional recovery
R hibernating myocardium). We limited our search
o humans and adults (older than 19 years of age) in
eer-reviewed journals from 1966 to June 2011. No
anguage restriction was applied. The reference lists of
ibliographies of identified articles were also reviewed.
rials in the abstract form without a manuscript
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496Selection criteria. To be included in the analysis, a
rial had to fulfill the following criteria: 1) prospec-
ive study involving patients with CAD in whom a)
MR was performed before revascularization (i.e.,
CI or CABG) in order to assess viability, and b)
ny current standard evaluation technique for left
entricular regional and/or global function was
erformed to assess improvement after revascular-
zation; 2) assessment of viability was performed in
atients only with chronic stable LV dysfunction at
east 2 weeks after myocardial infarction to avoid
tunning myocardium; 3) study allowed for sensi-
ivity, specificity, NPV, and PPV calculations; and
) there was use of standardized cutoffs for each
echnique, or the study provided enough data to
alculate diagnostic and predictive accuracies using
hese cutoffs.
Data extraction. Two investigators (J.R. and W.G.)
extracted the data independently and in duplicate.
Data was extracted using standardized protocol and
reporting forms. Disagreements were resolved by
arbitration (J.R. or M.J.G.), and consensus was
reached after discussion. We extracted characteris-
tics of each trial, interval between revascularization
and follow-up CMR, methods, baseline demo-
graphics, and number of viable and nonviable seg-
ments predicted at baseline and after the revascu-
larization for our analysis. In instances where these
values were not readily available, the main investi-
gator of that particular trial was approached to
supply the relevant information.
Quality assessment. To assess the quality and re-
porting of studies, we evaluated 14 items that were
considered relevant to the review topic, based on
the quality assessment of diagnostic accuracy studies
instrument (QUADAS) (21). Two reviewers (J.R.
and W.G.) independently assessed the quality
items, and discrepancies were resolved by consen-
sus. These items covered patient spectrum, refer-
ence standard, disease progression bias, verification
bias, review bias, clinical review bias, incorporation
bias, test execution, study withdrawals, and indeter-
minate results.
Statistical analysis. Sensitivities (number of viable
egments estimated by the test divided by the total
umber of segments with improved function after
evascularization), specificities (number of nonvia-
le segments estimated by the test divided by the
otal number of segments without improved func-
ion after revascularization), PPV (segments with
ecovery after revascularization divided by test-
iable segments), and NPV (segments without re-overy after revascularization divided by test-
onviable segments) were calculated for every study.
Several methods for meta-analysis of diagnostic
ests have been developed lately. Some methods are
esigned to be used with individual patient data of
he studies. Some methods are applicable when only
ensitivity and specificity for each study is available,
uch as the situation in this paper, which is most
ommonly seen in practice. A commonly used and
tandard method for such situation is the summary
eceiver-operating characteristic (ROC) method
22,23). This approach coverts each pair of sensi-
ivity and specificity values into a single measure of
ccuracy, the diagnostic odds ratio. However, sum-
ary ROC does not distinguish between the ability
f detecting the sick (sensitivity) and identifying the
ell (specificity). Discriminating between these
bilities is important to determine the optimal use
f a test in clinical practice. Therefore, in this
eta-analysis, we estimated summary sensitivity
nd specificity using a more recently developed
ivariate random effects model instead (24).
The bivariate approach assumed logit transforms
f sensitivity and specificity from individual studies
re from a bivariate normal distribution. The bi-
ariate approach is considered to be a better ap-
roach as compared with the standard summary
OC approach because first, it assesses heteroge-
eity across studies in sensitivity and specificity, and
rovides a summary estimate of sensitivity and
pecificity; second, it models sensitivity and speci-
city jointly so that a 95% confidence ellipse around
he summary estimate can be calculated; third, it
llows one to directly compare sensitivity and spec-
ficity between methods; further, several choices are
vailable to obtain a summary ROC curve (24,25).
In this paper, the summary ROC curve was ob-
tained by transforming the regression line of logit
sensitivity on logit specificity into ROC space (25).
A similar bivariate approached was used to model
PPV and NPV (26). Publication bias was assessed
for each technique using Egger’s, Macaskill’s, and
Deeks’s methods. Deeks et al. (27) recently pointed
out that Egger’s and Macaskill’s methods may be
misleading because their type I error rates are
typically inflated and can have low power when
diagnostic odds ratios are heterogeneous.
We assessed between-study heterogeneity visu-
ally, by plotting sensitivity and specificity in the
ROC curves. We also drew summary ROC curves
and confidence regions for summary sensitivity and
specificity (24,28).
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497The analyses were conducted using SAS (SAS
version 9.2, 2002 to 2008, SAS Institute, Cary,
North Carolina), and the figures were generated
using R (R version 2.12.2, 2011, The R Foundation
for Statistical Computing, Vienna, Austria).
Sensitivity analysis. We further evaluated whether
the performance of each technique depends on
features of the technique and patient characteristics.
A logistic regression for each technique was used to
model the sensitivity on these factors. For DE
CMR, the standard deviation cutoff value, the
follow-up time after the procedure and the propor-
tion of males and average age for the study popu-
lation were examined. No factor has been identified
that had a significant influence on its sensitivity; for
LDD, the follow-up time after the procedure and the
proportion of males in the study population had a
significant impact on its sensitivity (p  0.001 for
both): the longer the follow-up time and the more
men in the study, the higher the sensitivity; for
EDWT, the follow-up time, the proportion of males
in the study, and the mean age of the population all
had a significant impact on its sensitivity; however, the
longer the follow-up and the more men in the study,
the lower the sensitivity. But older age is associated
with higher sensitivity for EDWT, and the cutoff
value (5.5 vs. 6.0) for viability is not associated with its
sensitivity.
R E S U L T S
Study selection. We identified 12,200 articles, out
of which 8,705 abstracts were retrieved and re-
viewed for possible inclusion (Fig. 1). Twenty-four
studies (Tables 1, 2, and 3) enrolling 698 patients
(mean age 62 years; 83% men) and a total of 6,404
LV segments fulfilled the inclusion criteria and
were included in the analysis. Fourteen studies were
excluded from the final analysis because they did
not meet the inclusion criteria: 5 used a different
CMR technique (pixel-tracking–derived myocar-
dial deformation imaging [29], regional systolic
myocardial strain [30,31], diffusion-tensor CMR
[32], and non–contrast-enhanced myocardial rim
[33]); 3 DE CMR studies used a different cutoff
(34–36); 3 studies provided no data to calculate
diagnostic accuracies (37–39); 2 LDD CMR stud-
ies had no data available to calculate sensitivity/
specificity (40,41); 1 study used high-dose dobut-
amine 15 g/kg/min (42); and an EDWT study
did not provide data to calculate diagnostic accu-
racies (43).Baseline characteristics. Of the 24 studies, 11 stud-
es (10,44 –53) enrolling 331 patients (mean age
4 years; 83% men) and analyzing 4,397 LV
egments evaluated myocardial viability using DE
MR, 10 studies used cine-CMR for follow up,
nd only 1 used echocardiography. Nine studies
36,45,51,54 –59) with 247 patients (mean age 62
ears; 79% men) and 1,120 LV segments evalu-
ted myocardial viability using LDD CMR with
ll of them using cine-MRI for follow up, and 4
tudies (45,55,59,60) with 120 patients (mean
ge 57 years; 92% men) and 887 LV segments
valuated myocardial viability using EDWT
MR (Tables 1, 2, and 3).
Quality assessment. Reporting was especially poor
on item 11 (“Were the reference standard results
interpreted without knowledge of the results of the
index test?”); this refers to blinding and might have
led to inflated measures of diagnostic accuracy,
which is known as a review bias. Twelve percent of
the articles did not explain withdrawals from the
studies, indicating that test performance may intro-
duce a bias. Otherwise, all the studies showed
high-quality scores in the remaining 12 items of
Records identified through data 
base sources and other methods
(n=12,200)
Records after duplicate removed 
(n=8,705)
Records Screened
(n=8,705)
Full-text assessed for eligibility
(n=281)
Studies included in qualitative synthesis
(38)
Records excluded on the
of title and/or abstra
(n=8,424)
Full article excluded du
acute heart failure AMI 
Lack of revasc (n=11
Lack of post-revasc follow-u
Trials excluded (n=14
Incomplete data (n=5
Different cutoff for viabilit
Different viability method
Studies included (n=24)
DE (N=11)
LDD (N=9)
EDWT (N=4)
Figure 1. Selection of Studies
Fourteen studies were excluded from the ﬁnal analysis: 5 used a di
CMR technique (pixel-tracking–derived myocardial deformation ima
[29], regional systolic myocardial strain [30,31], diffusion-tensor CMR
non–contrast-enhanced myocardial rim [33]), 3 DE CMR studies use
ferent cutoff (34–36), 3 studies provided no data to calculate diagn
accuracies (37–39), 2 LDD CMR studies had no data available to cal
sensitivity/speciﬁcity (40,41), 1 study used high-dose dobutamine 1
min (42), and an EDWT study did not provide data to calculate diag
accuracies (43). AMI  acute myocardial infarction; CMR  cardiac
resonance; DE  contrast delayed enhancement; EDWT  end-dias
thickness; LDD  low-dose dobutamine. basis
ct
e to
(48)
2)
p (n=83)
)
)
y (n=3)
 (n=6)
fferent
ging
[32],
d a dif-
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culate
5 g/kg/
nostic
magnetic
tolic wallQUADAS (Figs. 2 and 3).
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498Publication bias. Using Egger’s or Macaskill’s meth-
ods, there is no indication of publication bias for
any of the 3 techniques. Likewise, Using Deeks’s
test, there is no indication of publication bias for
DE and EDWT CMRs (p  0.43 and 0.47,
respectively). However, a borderline significance
indicates that there might be some possibility of
publication bias in LDD CMR (p  0.05). This
indicates that some studies reporting negative re-
sults for this technique might not have been sub-
mitted for publication, and if they were, they were
never published.
racteristics of Studies Included in the Meta-Analysis Using CMR W
Study
Design n
Male
(%)
Age
(yrs)
LVEF
(%) Revascularization
Follow-Up
MRI
(Weeks)
ospective 21 62 59 41 CABG/PCI 36
ospective 36 84 62 39 CABG 12
ospective 20 95 64 29 CABG 24
ospective 43 88 63 43 CABG/PCI 11
ospective 29 72 66 32 CABG/PCI 24
ospective 33 94 66 38 CABG 24
ospective 12 83 61 NR CABG/PCI 12
ospective 29 79 62 28 CABG 6
ospective 52 NR NR 62 CABG 24
ospective 29 93 68 NR CABG/PCI 12
ospective 27 78 66 38 CABG 24
pass graft; CMR cardiac magnetic resonance; DE contrast delayed enhanceme
ction; NR  not reported.
racteristics of Studies Included in the Meta-Analysis Using CMR W
Study
Design n
Male
(%)
Age
(yrs)
LVEF
(%) Revascularization
Prospective 43 93 58 42 CABG/PCI
Prospective 52 48 58 41 CABG/PCI
05 Prospective 20 95 64 29 CABG
00 Prospective 10 80 69 44 PCI
1999 Prospective 25 88 58 NR CABG/PCI
Prospective 10 70 NR NR CABG/PCI
4 Prospective 40 92 57 42 CABG/PCI
04 Prospective 18 56 62 52 CABG/PCI
2004 Prospective 29 93 68 NR CABG/PCIine; other abbreviations as in Table 1.Delayed enhancement CMR. A total of 11 studies
evaluated myocardial viability using DE. The
follow-up CMR was performed between 6 and 36
weeks (mean 19 weeks) after revascularization.
This difference in follow-up did not reach statis-
tical significance. Also, some studies used a dif-
ferent standard deviation to define hyperen-
hancement, ranging from 2 to 6 SD (mean of
3.28 SD), which did not show any significance.
Gadolinium was administered as a contrast in all
studies, and images were obtained 6 to 25 min
after administration.
DE
chnique to
sess LVEF
Time After
Gadolinium
Administration
(min)
Hyperenhancement
(SD Above Normal
Intensity)
Cutoff for
Viability (%)
CMR 15 3 50
CMR 13 5 50
CMR 15 2 50
CMR NR 6 50
CMR 15 3 50
CMR 6 2 50
CMR 15 NR 50
ECHO 25 NR 50
CMR 10 2 50
CMR 13 NR 50
CMR 15 NR 50
SE dobutamine stress echocardiography; ECHO echocardiography; LVEF
LDD
ollow-Up
CMR
(Weeks)
Technique to
Assess LVEF
Dobutamine Dose
(g/kg/min)
Cutoff for
Viability (mm)
20 CMR 10 2
NR CMR 5–10 2
24 CMR 5–10 2
24 CMR 5 2
12 CMR 10 2
6 CMR 5–10 2
20 CMR 10 2
36 CMR 10 2
12 CMR 5–10 2Table 1. Baseline Cha ith
First Author
(Ref #), Year
Te
As
Becker et al. (44),
2008
Pr
Bondarenko et al.
(53), 2007
Pr
Gutberlet et al.
(45), 2005
Pr
Kim et al. (10),
2000
Pr
Kuhl et al. (46),
2006
Pr
Pegg et al. (47),
2010
Pr
Sandstede et al.
(48), 2000
Pr
Schvartzman
et al. (49), 2003
Pr
Selvanayagam
et al. (50), 2004
Pr
Wellnhofer et al.
(51), 2004
Pr
Wu et al. (52),
2007
Pr
CABG coronary artery by nt; DTable 2. Baseline Cha ith
First Author
(Ref #), Year
F
Baer et al. (55), 1998
Baer et al. (54), 2000
Gutberlet et al. (45), 20
Lauerma et al. (56), 20
Sandestede et al. (57),
Sayad et al. (58), 1998
Schmidt et al. (59), 200
Van Hoe et al. (36), 20
Wellnhofer et al. (51),
t
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499All the studies included used 50% of LV wall
hyperenhancement as a cutoff to determine whether
or not a LV segment was viable (i.e., 50%
hyperenhancement was deemed viable and 50%
hyperenhancement was deemed nonviable). The
weighted mean sensitivity and specificity were 95%
(95% confidence interval [CI]: 93% to 97%) and
51% (95% CI: 40% to 62%), whereas the PPV was
69% (95% CI: 56% to 80%) and NPV was 90%
(95% CI: 85% to 93%) (Table 4). This technique
had a weighted overall accuracy of 70% (95% CI:
69% to 71%).
DE CMR using <0%, <25%, and <75% as cutoffs. Of
he 11 studies evaluating hibernating myocardium
sing DE CMR, only 6 studies reported their
esults by quartiles. A total of 214 patients and
,365 LV segments were analyzed.
CUTOFF <0%. The weighted sensitivity and speci-
ficity for this cutoff were 0.53 (95% CI: 0.50 to
0.55) and 0.87 (95% CI: 0.85 to 0.88), whereas the
PPV and NPV were 0.77 (95% CI: 0.75 to 0.80)
and 0.68 (95% CI: 0.66 to 0.70), respectively.
CUTOFF <25%. The weighted sensitivity and speci-
ficity were 0.78 (95% CI: 0.76 to 0.80) and 0.71
(95% CI: 0.69 to 0.73), whereas the PPV and NPV
were 0.70 (95% CI: 0.67 to 0.72) and 0.79 (95% CI:
0.77 to 0.81), respectively.
CUTOFF <75%. The weighted sensitivity and speci-
ficity for this cutoff were 0.99 (95% CI: 0.99 to
1.00) and 0.21 (95% CI: 0.19 to 0.22), whereas the
PPV and NPV were 0.52 (95% CI: 0.50 to 0.54)
and 0.97 (95% CI: 0.96 to 0.99), respectively.
Dobutamine stress CMR. A total of 9 studies were
valuated using this method to evaluate for myo-
ardial viability. Each study used a 2-mm change in
V wall motion during LDD infusion (5 to 10
g/kg/min) as a cutoff to classify a segment as
viable or not. Each study performed the second
CMR also between 6 and 36 weeks (mean 19
weeks) after revascularization. There was no statis-
Table 3. Baseline Characteristics of Studies Included in the Met
First Author
(Ref #), Year Study Design n
Male
(%)
Age
(yrs)
Baer et al. (55), 1998 Prospective 43 93 58
Gutberlet et al. (45), 2005 Prospective 20 95 64
Klow et al. (60), 1997 Prospective 17 88 63
Schmidt et al. (59), 2004 Prospective 40 92 57
EDWT  end-diastolic wall thickness; other abbreviations as in Table 1.tical difference in terms of revascularization proce-dure (CABG vs. PCI). In these studies, the mean
weighted sensitivity and specificity were 81% (95%
CI: 73 to 86) and 91% (95% CI: 84% to 95%),
whereas the PPV and NPV were 93% (95% CI:
87% to 97%) and 75% (95% CI: 65% to 83%),
respectively (Table 5). The weighted overall accu-
acy for this technique was 84% (95% CI: 82%
o 86%).
EDWT CMR. Only 4 studies fulfilled the inclusion
riteria for this method. The cutoff used was
DWT of 5.5 to 6.0 mm for each study. The
ollow-up CMR was performed between 20 to 88
eeks (mean 38 weeks). The mean weighted sen-
itivity and specificity were 96% (95% CI: 91% to
8%) and 38% (95% CI: 23% to 57%), whereas the PPV
nd NPV were 71% (95% CI: 49% to 86%) and 85%
95% CI: 70% to 93%), respectively (Table 6). EDWT
MR had a weighted overall accuracy of 68% (95% CI:
6% to 70%).
The bivariate model showing summary diagnostic
ccuracies and comparing every method versus each
ther are shown in Table 7. Forest plots and ROC
urves are displayed in Figures 4A to 4C and 5A to 5C,
respectively.
D I S C U S S I O N
In modern medicine, viability tests are routinely
performed on subjects in whom revascularization is
being considered. Allman et al. (61) demonstrated a
strong association between viable myocardium on
noninvasive testing and increased survival after
revascularization with a reduction in annual mor-
tality of 79.6% compared with medical therapy
(3.2% vs. 16%). Hence, the 2009 guidelines for the
diagnosis and management of heart failure in adults
by the American College of Cardiology and the
American Heart Association recommend noninva-
sive imaging in patients with heart failure who have
known CAD and no angina (Class IIa, Level of
Evidence: B), based on the fact that CABG or PCI
alysis Using CMR With EDWT
LVEF
(%) Revascularization
Follow-Up
CMR
(Weeks)
Technique
Assess LV
42 CABG/PCI 20 CMR
29 CABG 24 CMR
40 CABG 88 CMR
42 CABG/PCI 20 CMRa-An
to
EF
Cutoff for
Viability (mm)
5.5
6
6
5.5is recommended in patients with chest pain regard-
her
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500less of the degree of ischemia or viability (62).
Nonetheless, no assessment modality is specified as
Baer (EDWT) 1998
Baer (LDD) 1998
Baer (LDD) 2000
Becker (DE) 2008
Bordarenko (DE) 2007
Gutberlet (DE) 2005
Gutberlet (EDWT) 2005
Gutberlet (LDD) 2005
Kim et al. (DE) 2000
Klow (EDWT) 1997
Kuhl (DE) 2006
Lauerma et al (LDD) 2000
Pegg (DE) 2010
Sandstede (DE) 2000
Sandstede (LDD) 1999
Sayad (LDD) 1998
Schmidt (EDWT) 2004
Schmidt (LDD) 2004
Schvartzman (DE) 2003
Selvanayagam (DE) 2004
Van Hoe (LDD) 2004
Wellnhofer (DE) 2004
Wellnhofer (LDD) 2004
Wu (DE) 2007
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501modality, but these claims have not been systemat-
ically evaluated. The current study aimed at com-
paring the diagnostic and predictive accuracies of 3
different assessment methods that have been stud-
ied.
Our meta-analysis indicates that among CMR
methods, DE CMR provides the highest sensitivity
as well as the highest NPV for predicting improved
segmental LV contractile function after revascular-
ization, followed by EDWT CMR, whereas LDD
CMR demonstrated the lowest sensitivity/NPV
among all modalities. On the other hand, LDD
Representativ
Selection criteri
Acceptable referen
Acceptable delay be
Partial verificat
Differential verificat
Incorporat
Index test described in detail to permi
Reference standard described in detail to permi
Index test res
Reference standard res
Relevant clinical
Uninterpretable resu
Withdrawa
Yes (high quality)
Figure 3. Methodological Quality Graph
Reporting was especially poor on item 11 (“Were the reference stan
index test?”); this refers to blinding and might have led to inﬂated
Twelve percent of the articles did not explain withdrawals from the
wise, all the studies showed high-quality scores in the remaining 12
Table 4. Sensitivities/Speciﬁcities and Predictive Values of DE C
First Author
(Ref #), Year
Sensitivity (%)
Segments
Becker et al. (44), 2008 95 (215/227)
Bordarenko et al. (53), 2007 93 (79/85)
Gutberlet et al. (45), 2005 99 (198/200)
Kim et al. (10), 2000 97 (411/425)
Kuhl et al. (46), 2006 98 (94/96)
Pegg et al. (47), 2010 96 (381/397)
Sandstede et al. (48), 2000 97 (39/40)
Schvartzman et al. (49), 2003 94 (95/101)
Selvanayagam et al. (50), 2004 95 (323/340)
Wellnhofer et al. (51), 2004 90 (111/124)
Wu et al. (52), 2007 92 (142/154)
Weighted mean 95
Segments are given as % (n/N).
NPV  negative predictive value; PPV  positive predictive value; other abbreviatCMR offered the highest specificity and PPV,
followed by DE CMR, whereas EDWT showed
the lowest of these parameters. LDD CMR also
provided the highest diagnostic odds ratio, suggest-
ing that it has the best overall performance; how-
ever, the difference with the other 2 methods is not
statistically significant, therefore this result needs to
be interpreted cautiously.
By comparing these values with those reported
for 4 different imaging modalities in 2 compelling
meta-analyses published by Bax et al. (9) and
Schinkel et al. (20), it is clearly seen that DE CMR
pectrum?
scribed?
tandard?
en tests?
avoided?
avoided?
avoided?
lication?
lication?
 blinded?
 blinded?
rmation?
eported?
plained?
clear
0% 25% 50% 75% 100%
No (low quality)
d results interpreted without knowledge of the results of the
sures of diagnostic accuracy, which is known as a review bias.
dies indicating that test performance may introduce a bias. Other-
s of QUADAS (quality assessment of diagnostic accuracy studies).
Speciﬁcity (%)
Segments
PPV (%)
Segments
NPV (%)
Segments
42 (100/236) 61 (215/351) 89 (100/122)
38 (92/237) 35 (79/224) 94 (92/98)
94 (30/32) 99 (198/200) 98 (30/32)
44 (168/379) 66 (411/622) 92 (168/182)
70 (64/91) 78 (94/121) 97 (64/66)
59 (332/560) 63 (381/609) 96 (332/348)
76 (25/33) 83 (39/47) 96 (25/26)
25 (27/106) 55 (95/174) 81 (27/33)
26 (71/272) 62 (323/524) 80 (71/88)
52 (85/164) 58 (111/190) 86 (85/98)
45 (44/98) 73 (142/196) 78 (44/56)
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502provides the highest sensitivity and NPV (95% and
90%) for predicting functional improvement after
revascularization of hibernating myocardium of any
other technique in clinical practice (i.e., PET-FDG
[92% and 87%], rest-redistribution thallium-201-
SPECT [87% and 79%], technetium-99m
sestamibi-SPECT [83% and 76%], and DSE [80%
and 83%]). Similarly, LDD CMR provides the
highest specificity and PPV (91% and 93%) com-
pared with any other modality, including PET-
FDG (63% and 74%), rest-redistribution thallium-
201 SPECT (54% and 67%), technetium-99m
sestamibi SPECT (65% and 74%), and DSE (78%
and 75%).
Having the highest NPV, DE CMR allows for
physician confidence in evaluating the appropriateness
of revascularization therapy in selected patients.
Likewise, having the highest PPV, LDD CMR
would prevent patients from undergoing unneces-
sary high-risk revascularization procedures. It has
been shown that the annual mortality rate is ap-
proximately 3.2% after revascularization in pa-
tients with viable myocardium as compared with
7.7% in those without evidence of viable myocar-
dium. Furthermore, the perioperative mortality is
almost insignificant for patients with viable myo-
Table 5. Sensitivities/Speciﬁcities and Predictive Values of Dobu
First Author
(Ref #), Year
Sensitivity (%)
Segments
Baer et al. (55), 1998 89 (24/27)
Baer et al. (54), 2000 86 (24/28)
Gutberlet et al. (45), 2005 88 (183/208)
Lauerma et al. (56), 2000 75 (43/57)
Sandstede et al. (57), 1999 61 (65/106)
Sayad et al. (58), 1998 89 (25/28)
Trent et al. (42), 2000 71 (81/114)
Van Hoe et al. (36), 2004 78 (56/72)
Wellnhofer et al. (51), 2004 75 (93/124)
Weighted mean 81
Segments are given as % (n/N).
Abbreviations as in Tables 1 and 4.
Table 6. Sensitivities/Speciﬁcities and Predictive Values of EDW
First Author
(Ref #), Year
Sensitivity (%)
Segments
Baer et al. (55), 1998 94 (176/188)
Gutberlet et al. (45), 2005 96 (216/225)
Klow et al. (60), 1997 98 (63/64)
Schmidt et al. (59), 2004 100 (25/25)
Weighted mean 96
Segments are given as % (n/N).
Abbreviations as in Tables 1, 3, and 4.cardium and as high as 10% in those without
viability (63– 65).
Identification of hibernating myocardium in pa-
tients with CAD and LV dysfunction was per-
formed by Shimoni et al. (12), comparing 3 differ-
ent modalities head to head: 1) myocardial contrast
echocardiography; 2) thallium-201 (Tl201) scintig-
raphy; and 3) dobutamine echocardiography. The
sensitivities for functional recovery were 90%, 92%,
and 80%, respectively. On the other hand, the
reported specificity for each technique was 63%,
45%, and 54%, respectively (12). In the ischemic
cascade, perfusion abnormalities occur earlier than
contractile abnormalities. This explains why several
studies have shown higher sensitivity for nuclear
perfusion imaging compared with contractile re-
serve (12,66). Scar formation, which is measured by
DE MRI, is the last manifestation in the ischemic
cascade; that is why presence of DE should have the
highest sensitivity to predict absence of recovery.
The superiority of CMR to echocardiography and
nuclear techniques might be attributed to 2 main
factors: 1) CMR has higher spatial resolution com-
pared with SPECT or PET, by which it can provide
a more precise delineation of scar tissue; and 2)
contrast-enhanced echocardiography may potentially
ine Stress CMR
eciﬁcity (%)
Segments
PPV (%)
Segments
NPV (%)
Segments
94 (15/16) 96 (24/25) 83 (15/18)
92 (22/24) 92 (24/26) 85 (22/26)
89 (32/36) 97 (183/187) 56 (32/57)
00 (29/0) 100 (43/43) 67 (29/43)
90 (91/101) 87 (65/75) 43 (91/132)
93 (14/15) 96 (25/26) 82 (14/17)
70 (163/232) 54 (81/150) 83 (163/196)
82 (37/45) 88 (56/64) 70 (37/53)
93 (152/164) 86 (93/105) 83 (152/183)
91 93 75
R
peciﬁcity (%)
Segments
PPV (%)
Segments
NPV (%)
Segments
52 (113/219) 62 (176/282) 90 (113/125)
35 (11/31) 92 (216/236) 55 (11/20)
19 (23/120) 40 (63/160) 96 (23/24)
53 (8/15) 78 (25/32) 100 (8/8)
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503identify nonperfused scarred myocardial segments, but
this technique is greatly limited by attenuation and
bubble destruction artifacts (67–69).
DE Studies
Becker 2008
Bordarenko 2007
Gutberlet 2005
Kim 2000
Kuhl 2006
Pegg 2010
Sandstede 2000
Schvartzman 2003
Selvanayagam 2004
Wellnhofer 2004
Wu 2007
Summary
Sensitivity
0.8 0.85 0.9 0.95 1
LDD Studies
Baer 1998
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Gutberlet 2005
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Baer 1998
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Figure 4. Forest Plots of Sensitivity and Speciﬁcity
(A) DE CMR, (B) LDD CMR, and (C) EDWT CMR: the size of the squa
Horizontal lines are the 95% conﬁdence intervals, and the summar
Table 7. Summary Estimates for Sensitivity, Speciﬁcity, and DO
CMR Mean Sensitivity (95% CI) Mean Speciﬁc
DE CMR 0.95 (0.93–0.97) 0.51 (0.4
LDD CMR 0.81 (0.73–0.86) 0.91 (0.8
EDWT CMR 0.96 (0.91–0.98) 0.38 (0.2
p Value DE vs. LDD 0.001 0.0
p Value DE vs. EDWT 0.89 0.
p Value LDD vs. EDWT 0.001 0.0
CI  conﬁdence interval; DOR  diagnostic odds ratio; other abbreviations asapproach. Abbreviations as in Figure 1.On the basis of our analysis, performing a LDD
CMR may be useful in high operative risk patients
who have a positive DE CMR in order to obtain a
DE Studies
Becker 2008
Bordarenko 2007
Gutberlet 2005
Kim 2000
Kuhl 2006
Pegg 2010
Sandstede 2000
Schvartzman 2003
Selvanayagam 2004
Wellnhofer 2004
Wu 2007
Summary
Specificity
0.2 0.4 0.6 0.8 1
LDD Studies
Baer 1998
Baer 2000
Gutberlet 2005
Lauerma 2000
Sandstede 1999
Sayad 1998
Schmidt 2004
Van Hoe 2004
Wellnhofer 2004
Summary
Specificity
0.6 0.7 0.90.8 1
EDWT Studies
Baer 1998
Gutberlet 2005
Klow 1997
Schmidt 2004
Summary
Specificity
0.1 0.2 0.40.3 0.5 0.70.6 0.8
lotting symbol is proportional to the same size for each study.
nsitivity and speciﬁcity are calculated based on the bivariate
om the Bivariate Model
(95% CI) Mean DOR (95% CI) PPV (95% CI) NPV (95% CI)
62) 21.12 (10.98–40.55) 0.69 (0.56–0.80) 0.90 (0.85–0.93)
95) 41.57 (18.25–94.68) 0.93 (0.87–0.97) 0.75 (0.65–0.83)
57) 13.33 (4.16–42.74) 0.71 (0.49–0.86) 0.85 (0.70–0.93)
0.21 0.001 0.001
0.34 0.87 0.37
0.08 0.01 0.21
bles 1, 2, 3, and 4.re p
y seR Fr
ity
0–0.
4–0.
3–0.
01
25
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ations as in Figure 1.
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504higher specificity and thus higher PPV. Conversely,
DE CMR could similarly be added to LDD CMR
in low operative risk patients with a negative LDD
test to obtain a higher sensitivity and NPV. Since
DE CMR is easier to perform and carries a lower
complication risk and since its sensitivity/NPV is
higher than LDD CMR’s specificity/PPV, DE
CMR should probably be used as the first-line
assessment. This approach has previously suggested
by Kaandorp et al. (70); in their study, DE CMR
and LDD CMR were compared head to head on
the same patients in order to evaluate myocardial
viability. The authors concluded that LDD CMR
might be an option when patients have an interme-
diate extent of scar to ultimately differentiate viable
from nonviable myocardium (70).
It is worth pointing out that the low specificity
and PPV of DE CMR might be due to the fact that
investigators have had to use a particular cutoff of
50% for research purposes in order to differentiate
viable from nonviable myocardium. As described
first by Kim et al. (10) and Van Hoe et al. (36) a few
years later, myocardial viability should not be inter-
preted as an all-or-none phenomenon for 2 reasons:
1) although segments without any degree of hyper-
enhancement have a high PPV (92%), segments
with partial hyperenhancement (0% to 50%) have a
less predictable response to revascularization; and
2) different degrees of wall motion abnormalities
have a major impact on myocardial recovery, with
segments showing akinesia and dyskinesia demon-
strating the best recovery (sensitivity 92%, NPV
96%, specificity 86%, and PPV 73%) (10,36).
In order to take the aforementioned situation
into account, we carried out a subanalysis on DE
CMR studies that reported their findings by quar-
tiles. Our results mainly showed that using a cutoff
of 0% to define viable myocardium significantly
improves the specificity and PPV of this technique
as compared with using a cutoff of 50%. On this
basis, patients without any degree of hyperen-
hancement might not require LDD CMR to
optimally differentiate viable myocardium. Yet, it
is important to remember that the values ob-
tained using a cutoff of 0% for DE CMR are
not as high as those provided by LDD CMR
(87%, 77% vs. 91%, 93%).
In addition to providing 1 of the best diagnostic
accuracy values, CMR can also provide valuable
information in assessing LV function, LV volumes,
and the presence of either functional mitral regur-
gitation or aneurysm that might be suitable forSe
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Figure 5. ROC Curves
Bivariate summary estimate of sensitivity and speciﬁcity for (A) DE
CMR, (B) LDD CMR, and (C) EDWT CMR and the corresponding
95% conﬁdence ellipse around its mean value. The solid square in
the center represents the mean speciﬁcity and speciﬁcity. Each cir-
cle represents an individual study, whereas the size of each circle is
proportional to the sample size for each study. The solid curve is
the summary receiver-operating characteristic (ROC) curve. Abbrevi-repair at the time of CABG (71,72). Improvement
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505of LV systolic dysfunction is clinically important
because LV ejection fraction is a major determinant
of survival in patients with CAD (73). Although,
no CMR study among the trials in our meta-analysis
evaluated global LV function in terms of diagnostic
accuracy, the ejection fraction increased from 41% to
47% (p  0.007) in DE CMR studies, from 42% to
48% (p 0.03) in LDD CMR, and from 37% to 41%
(p  0.34) in EDWT CMR.
Two shortcomings of CMR are worth mention-
ing. First, CMR is contraindicated in many patients
with metallic implants. However, devices such as
intravascular stents, most prosthetic cardiac valves,
and prosthetic joints placed within the last 2 de-
cades are considered “MRI safe.” Pacemakers and
implantable cardioverter-defibrillators are still con-
sidered a strong relative contraindication to CMR
examination due to the risk of arrhythmia induc-
tion, device movement, and especially “lead heat-
ing” (74). However, a recent randomized clinical
trial evaluated CMR safety of a new implantable
cardiac device (MRI SureScan pacemaker system,
Medtronic, Minneapolis, Minnesota) in 200 pa-
tients, with no CMR-related complications re-
ported during or after the test (75,76).
Second, nephrogenic systemic fibrosis is a devas-
tating (albeit extremely rare) potential complication
in patients exposed to gadolinium-based contrast
agents. This complication occurs almost exclusively
in patients with moderate to severe renal disease,
particularly those on dialysis (77,78). The Food and
Drug Administration currently defines patients
with an estimated glomerular filtration rate of 30
ml/min as “at risk” for this complication.
Clinical implications. In light of having no single test
to accurately assess myocardial viability, it may be
advisable to combine the assessment of the degree of
transmurality scar tissue with DE CMR and the
assessment of the contractile reserve with LDD CMR
to obtain the best possible diagnostic and prognostic
information. Here, it has been clearly demonstrated
that DE CMR provides the highest sensitivity and
NPV for predicting LV recovery of functionality after
revascularization, whereas LDD CMR provides the
highest specificity and PPV of any currently available
test to evaluate myocardial viability. Supported by
these results, patients with 50% of DE should
ndergo LDD CMR to precisely differentiate viable
rom nonviable myocardium. The latter technique
ight not be entirely necessary if patients have no
yperenhancement in the LV wall.
The recent multicenter trial of “Coronary-Arteryypass Surgery in Patients with Left Ventricularysfunction” published by the STICH (Surgical
reatment for Ischemic Heart Failure) Investigators
as carried out in order to evaluate whether there is
ny benefit in terms of morbidity and mortality
etween medical therapy as compared with revascu-
arization therapy (79). This trial showed a significant,
lthough modest, reduction in the risk of death,
yocardial infarction, and other major cardiovascular
vents in patients randomized to CABG (79). More-
ver, a subanalysis of the STICH trial assessing the
alue of myocardial viability assessment suggested that
either echocardiographic nor nuclear scintigraphic
ethods helped in selecting patients for revasculariza-
ion (80). Hence, this study highlights the need to
nvestigate the role of more reliable tests to evaluate
atients with chronic LV dysfunction in whom a
evascularization intervention is being planned. It has
een clearly demonstrated in prospective trials that
E CMR has very low intraobserver and interob-
erver variability (81). Moreover CMR can also allow
or a more comprehensive evaluation of virtually every
spect of the cardiac anatomy and function. Whether
his will translate into increased ability to identify
hronic ischemic patients who will benefit from revas-
ularization remains to be determined.
Study limitations. An appropriate assessment of the
diagnostic accuracy for EDWT CMR was not
reached due to the limited number of studies and
the high level of heterogeneity in specificity. There
were few studies using CMR for the prediction of
recovery of global LV function after revasculariza-
tion. Similarly, no test evaluated improvement in
heart failure symptoms or exercise capacity. Given
the fact that a viability test is currently often chosen
based on physician preferences, availability, or ex-
perience with the test, it might not be suitable to
extrapolate these results widely. Other methods to
evaluate myocardial viability using CMR have also
been recently proposed. However, due to the small
number of studies, they could not be included in
this meta-analysis.
DE CMR and LDD CMR diagnostic accuracies
could not be statistically combined in order to
evaluate how adding these 2 methods will improve
sensitivity/specificity upon each technique sepa-
rately, given the fact that only 2 studies imple-
mented both LDD and DE techniques on the same
patients, and patient-level data was not provided in
these articles. Finally, results from LDD CMR
should be cautiously interpreted, given the border-
line significance for publication bias demonstrated
by Deeks’s test.
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Among CMR viability methods, DE CMR pro-
vides the highest sensitivity and NPV. Likewise,
LDD CMR provides the highest specificity and
PPV of any other modality. In light of these
findings, integrating these 2 methods should pro-resonance imaging to identify revers-
1
1
1
1
1
1
1
1
1
Cardiovascular magn
aging for detectionchronic LV dysfunction being considered for revas-
cularization.
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